Intellectual Product – Page 9

RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines

3 months ago talkbio0Tagged Autistic Disorder, Environment, HHS, Kennedy, RFK gene, Vaccines

Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

3 months ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg

3 months ago talkbio0Tagged Alarm device, Changing, Disease Outbreaks, drug safety, Icebergs, KAT5 wt Allele, Leadership, Policy, Previous, public health medicine (field), United States Food and Drug Administration, Vaccines, Visible

United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible

UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU

3 months ago talkbio0Tagged drug price, EU, Industry, Investments, Pharma, Policy, Transplant Registry Unified Management Program, United States

EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

3 months ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

3 months ago talkbio0Tagged Evaluation, global supply chain, Impact food supplement, Import, Manufacturing, pharmaceutical ingredients, pharmaceutical tariffs, Policy, regulatory, reshoring, Sectioning technique, supply chain exposure, TNFRSF19 gene, United States

U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact

Trump pledges his support for a change to the IRA long sought by drugmakers

3 months ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

J&J brushes off tariff headwinds with raised forecast, oncology surge

3 months ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Harvard Faces $2.2 Billion Federal Funding Freeze After Defying Trump Administration Demands

3 months ago talkbio0Tagged Academia (organization), Administration occupational activities, antisemitism, battle, campus, civil, DEI, Diversity, federal, Freezing, Harvard University, Legal, protest, Research Projects, R-Series, Status, Transplant Registry Unified Management Program, university governance

Harvard University, Trump administration, federal funding freeze, $2.2 billion, research grants, diversity equity inclusion (DEI), antisemitism, academic independence, campus protests, Title VI, civil rights, university governance, legal battle, tax exempt status

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

3 months ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.